What is the recommended beta‑blocker regimen and dosing for migraine prophylaxis, and what alternatives should be used for patients with contraindications such as asthma, severe bradycardia, or uncontrolled hypotension?

Beta-Blockers for Migraine Prophylaxis

Start with propranolol or metoprolol as first-line beta-blocker therapy for migraine prevention in adults without contraindications, using propranolol 80-240 mg daily or metoprolol 100-200 mg daily in divided doses. 1, 2

Recommended Beta-Blocker Regimen

The most recent 2025 American College of Physicians guideline establishes beta-blockers (specifically metoprolol and propranolol) as preferred first-line agents for episodic migraine prophylaxis, prioritizing them alongside valproate, venlafaxine, and amitriptyline before considering more expensive CGRP-targeted therapies 1. This recommendation is driven by comparable efficacy to newer agents but with substantially lower cost and patient preference for oral medications.

Specific Beta-Blockers and Dosing:

First-choice agents:

• Propranolol: 80-240 mg daily in divided doses (most evidence-based)
• Metoprolol: 100-200 mg daily in divided doses
• Atenolol: 50-100 mg daily
• Bisoprolol: 5-10 mg daily 2

Critical distinction: Only beta-blockers without intrinsic sympathomimetic activity (ISA) are effective 2, 3. Avoid alprenolol, oxprenolol, pindolol, and acebutolol as they have ISA and lack proven efficacy in migraine prevention 3.

Expected Efficacy:

Beta-blockers reduce migraine days by approximately 1.27 days per month compared to placebo in patients averaging 8 migraine days monthly at baseline 4. While this appears modest, it represents clinically meaningful improvement when considering quality of life impact.

Absolute Contraindications to Beta-Blockers

Asthma and Severe Reactive Airway Disease:

This is a hard stop. Network meta-analysis demonstrates that oral timolol and intravenous propranolol significantly increase asthma exacerbations (RR 3.35 and 10.19 respectively) 5. In patients with baseline asthma history, oral labetalol, oxprenolol, propranolol, and metoprolol all show significantly higher asthma attack rates 5. Even cardioselective beta-blockers carry risk in severe asthma.

Other Absolute Contraindications:

• Severe bradycardia (<50 bpm at rest)
• Second or third-degree AV block
• Decompensated heart failure
• Uncontrolled hypotension (systolic BP <90 mmHg)
• Severe peripheral vascular disease

Alternative Prophylactic Agents When Beta-Blockers Are Contraindicated

Use this algorithmic approach:

First-Line Alternatives (equal standing per 2025 ACP guidelines):

1. Amitriptyline (tricyclic antidepressant): 10-150 mg nightly

   • Preferred if comorbid depression, anxiety, or insomnia 2
   • Reduces migraine days by 1.2 per month 4
   • Caution: anticholinergic effects, weight gain

2. Venlafaxine (SNRI): 75-150 mg daily

   • Good alternative with fewer anticholinergic effects than amitriptyline
   • Useful in comorbid depression 1

3. Valproate/Divalproex: 500-1000 mg daily in divided doses

   • Strictly contraindicated in women of childbearing potential due to teratogenicity 2
   • Reduces migraine days by approximately 1.4 per month
   • Consider only in men or postmenopausal women

4. Topiramate: 50-200 mg daily in divided doses

   • Reduces migraine days by 1.4 per month 4
   • Preferred if comorbid obesity (causes weight loss) 2
   • Higher adverse effect burden (cognitive effects, paresthesias) 1

5. Candesartan (ARB): 16 mg daily

   • Excellent choice if comorbid hypertension 2
   • Well-tolerated with minimal side effects

Second-Line Alternatives:

• Flunarizine: 5-10 mg nightly (not available in US)
• Naproxen: 500-1000 mg daily (for less frequent migraines)

Third-Line (After Multiple Failures):

CGRP monoclonal antibodies 1, 2:

• Erenumab, fremanezumab, galcanezumab, eptinezumab
• Reduce migraine days by 1.0-3.8 per month 4
• Excellent tolerability but substantially higher cost
• Reserved for patients failing 2-3 oral preventives per most guidelines

CGRP receptor antagonists (gepants):

• Atogepant, rimegepant
• Similar efficacy to monoclonal antibodies
• Oral administration preferred by patients over injectables 1

Special Populations Requiring Alternative Approaches

Older Adults:

Exercise caution with beta-blockers due to increased cardiovascular comorbidities 2. Consider candesartan or low-dose amitriptyline as safer first-line options.

Chronic Migraine (≥15 headache days/month):

No robust evidence supports beta-blockers for chronic migraine 2. Instead use:

1. Topiramate (first choice due to cost)
2. OnabotulinumtoxinA (155 units every 12 weeks)
3. CGRP monoclonal antibodies (proven effective even after multiple preventive failures) 2

Athletes/Active Individuals:

Beta-blockers may impair exercise tolerance. Prefer topiramate, candesartan, or CGRP-targeted therapies.

Critical Pitfalls to Avoid

1. Inadequate dosing: Many clinicians use subtherapeutic doses. Titrate to recommended ranges unless limited by side effects 6.

2. Insufficient trial duration: Assess efficacy only after 2-3 months at therapeutic dose 7. Premature discontinuation is common.

3. Using beta-blockers with ISA: These are ineffective for migraine 3.

4. Ignoring medication overuse headache: Prophylaxis fails if patients overuse acute medications (>2 days/week). Address this first 2.

5. Not considering comorbidities: Match the preventive to the patient's comorbidity profile for dual benefit 2.

Non-Pharmacological Adjuncts

When beta-blockers are contraindicated, strongly consider adding:

• Neuromodulatory devices (e-Nerivio, Cefaly, gammaCore)
• Cognitive behavioral therapy/biofeedback
• Acupuncture (though not superior to sham) 2

These can serve as stand-alone prevention when all medications are contraindicated or as adjuncts to enhance pharmacotherapy efficacy.